DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (NYSE Amex: AXK) today announced that it completed the sale of a non-exclusive license for its proprietary OptiChem® bio-coatings to an innovative, public diagnostics company. The licensee is paying $1,865,000 over four annual escalating payments and intends to use OptiChem® in its disposable diagnostic devices.
